Preston and Agre 1) first cloned the water channel protein named as an aquaporin (AQP) in the membrane of erythrocytes in 1991. Thirteen molecular species of AQPs, AQP0-12, have been identified to date. These AQPs were classified into two groups, AQP0, 1, 2, 4, 5, 6, and 8 and AQP3, 7, 9, 10, 11, and 12, the former group selectively permeabilizing water only and the latter, named as aquaglyceroporins, permeabilizing not only water, but also water-soluble low-molecular weight molecules such as glycerol and urea. Although AQPs are widely distributed in almost all human tissues, they show specific tissue localization.
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2) AQP1, 3, 4, 7, 8, 10, and 11 were reported to be expressed in the gastrointestinal tract and seem to play a role in absorption of water.
3) However, it is still unclear what substances other than water are permeabilized by these AQPs in these sites.
AQP3 has been observed expressed in human ileum, colon, jejunum, liver, and pancreas and highly expressed on basal membrane of epithelial cells in ileum and colon. 4) From observations in AQP3-deficient mice, AQP3 was speculated related to renal failure caused by nephrogenic diabetes insipidus and hydronephrosis, absorption of glycerol from decreases of glycerol levels in serum, skin hydration from promotion of dry skin, and occurrence of diarrhea and constipation. 2, 5) Although lethal dysfunctions caused by deficiency of AQP3 in mice have not been reported so far, AQP3 seems to be required to maintain healthy living. Itoh et al. 6) found that AQP3 expression was increased by treatment with vasoactive intestinal polypeptide (VIP) in human colonic epithelial cells and suggested that increased expression of AQP3 by VIP caused exacerbation of diarrhea because VIP was closely linked to diarrhea onset through controlling gastrointestinal peristaltic motion and secretion of water and electrolytes.
The physiological roles related to permeation of low-molecular weight molecules by AQP3 are still unclear in the gastrointestinal tract although the roles on water permeation were studied in depth as described above. mRNA expression of AQP7, a closely related species to AQP3 and classified as an aquaglyceroporin, was reported regulated by insulin in adipose cells. 7) Although the action mechanisms of insulin have been well studied, it has rarely been reported that AQPs are involved in the process of the insulin reaction. The finding of suppression of AQP7 expression by insulin suggests the possibility that insulin controls release of glycerol from adipose cells through AQP7. AQP7 probably contributes to decrease of blood glucose level. Since glycerol is involved in digested nutrients and AQP3 is able to permeabilize glycerol, as dose AQP7, it seems appropriate to consider that AQP3 is responsible for absorption of glycerol in digestive organs. Therefore we first examined whether AQP3 expression was affected by insulin and found that mRNA expression of AQP3 was decreased by treatment with insulin. Herein, we investigate how hormones including insulin and antidiabetic agents used for controlling blood glucose level affect AQP3 expression and the signal transduction pathway from insulin to gene expression of AQP3. Cell Culture and Treatment with Various Reagents Caco-2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 100 mg/ml streptomycin, and 100 units/ml penicillin. Cells were plated on a 35-mm dish at a density of 3ϫ10 6 cells/ml and incubated in a CO 2 incubator for 36 h. Cells were washed once with phosphate buffered saline then treated with serum-free medium containing 0.5% bovine serum albumin and various concentrations of reagents in a CO 2 incubator.
MATERIALS AND METHODS

Materials
Real Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) for AQP3 and b b-Actin Total RNAs were extracted from Caco-2 cells with TRIzol reagent. 1st-strand cDNAs were prepared from 5 mg of total RNA by SuperScript III reverse transcriptase and used as template cDNA. Real-time RT-PCR was performed using an iQ SYBR Green Supermix and iCycler iQ System (BIO-RAD Laboratories, Hercules, CA, U.S.A.). The specific primers used for amplification of AQP3 and b-actin were 5Ј-GACAGAAGG-AGCTGGTGTCC-3Ј and 5Ј-GGCTGTGCCTATGAACTG-GT-3Ј and 5Ј-CAAGTACTCCGTGTGGATCG-3Ј and 5Ј-AGTCCGCCTAGAAGCATTTG-3Ј, respectively.
Western Blotting Caco-2 cells treated with or without insulin were lysed with 1 % sodium dodecyl sulfate (SDS) and 4 mM 2-mercaptoethanol. SDS-polyacrylamide gel electrophoresis was carried out with 12 % polyacrylamide gel according to the method of Laemmli. 8) Western blotting was performed with goat anti-AQP3 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, U.S.A.) and anti-goat IgG peroxidase conjugate (Sigma-Aldrich, Saint Louis, MI, U.S.A.) using the method of Towbin et al. 9) Peroxidase activity was detected by an ECL Western Blotting Detection System according to the manufacturer's instructions (Amersham Biosciences). (Figs. 1A, B) . Protein expression of AQP3 was also observed to decrease 48 h after 1 mM insulin treatment (Fig.  1C) .
RESULTS
Effects of Hypoglycemic Agents on AQP3 Expression
AQP3 expression in cells treated with hypoglycemic reagents troglitazone, tolbutamide, and biguanides was also examined. Troglitazone and tolbutamide were demonstrated to decrease mRNA expression of AQP3 at concentrations of 10-100 mM for both drugs with 12 h of treatment ( Figs.  2A-D) . The concentration of 10 mM tolbutamide was within the concentration range used clinically. On the other hand biguanides metformin and buformin did not affect AQP3 expression within the concentrations indicated in Figs. 2E and F even though the concentrations of biguanides used in this experiment were much higher than those clinically used.
Effects of Hyperglycemic Hormones on AQP3 Expression mRNA expression of AQP3 in Caco-2 cells treated with approximately physiological concentrations of epinephrine and glucagon was measured. Epinephrine at concentrations of 1-100 nM for 12 and 24 h caused AQP3 expression to increase, whereas the expression was unaffected by treatment with glucagon (Fig. 3) .
Effects of Inhibitors of Signal Transduction Pathway on AQP3 Expression
To clarify the mechanism of suppression of AQP3 expression by treatment with insulin and troglitazone, signal transduction pathways regulating AQP3 expression were studied using inhibitors for the pathways. Wortmannin and rapamycin, inhibitors for phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR), respectively, were found to recover AQP3 expression decreased by insulin and troglitazone (Figs. 4A, B, D,  E) . Glycogen synthase kinase-3 (GSK-3) is located downstream of PI3K and is part of a different signaling pathway from the mTOR pathway. Lithium chloride, an inhibitor of GSK-3, did not affect expression of AQP3 and recovered the expression decreased by insulin and troglitazone (Figs. 4C,  F) .
It was also examined whether protein kinases A and C participated in the increase of AQP3 expression by epinephrine. Although calphostin C, an inhibitor for protein kinase C, suppressed increase of expression, the expression was unaffected by H89, an inhibitor for protein kinase A (Fig. 5) .
We summarize the effects of hormones and antidiabetic Cell lysates were prepared with lysis buffer containing SDS and 2-mercaptoethanol and separated by electrophoresis with 12% SDS-polyacrylamide gel. After proteins in the gel were electroblotted on a nitrocellulose membrane, AQP3 was probed with anti-AQP3 antibody and visualized by second antibody-peroxidase conjugate and ECL system. * pϽ0.05, **pϽ0.01 vs. control. agents for controlling blood glucose level on the expression of AQP3 mRNA in Table 1 and show the proposed pathways of the AQP3 expression regulated by insulin and epinephrine receptors signaling in Chart 1.
DISCUSSION
Insulin is well known to regulate transcription of various genes encoding enzymes in the metabolic pathways of glycolysis, gluconeogenesis, glycogen synthesis, and fatty acid synthesis. 10) We found that insulin significantly suppressed mRNA and protein expression of AQP3 in Caco-2 cells in this study. Although the hypoglycemic agents troglitazone and tolbutamide were also demonstrated to suppress AQP3 mRNA expression, biguanides metformin and buformin did not affect expression. Furthermore, treatment with epinephrine, a hyperglycemic hormone, resulted in increase of the AQP3 mRNA expression, but glucagons, exhibiting the same effect as epinephrine, did not elicit increased expression. Thus AQP3 may be expected to have direct or indirect involvement in the control of blood glucose level because of the finding that mRNA and protein expression of AQP3 is regulated by hormones and medicines that control blood glucose level. Since AQP3 has been reported to pass glycerol as well as water through plasma membranes, 2) it is likely that AQP3 in the gastrointestinal tract participates in absorption of glycerol in ingested nutrition. We could understand more clearly how AQP3 is involved in control of blood glucose level if we can measure how much glycerol as a source in glycolytic metabolism is carried by AQP3 in the gastrointestinal tract.
Signal transduction pathways of insulin have been studied in depth for enzymes involved in glycolytic metabolism, transporters, and proteins related to cell growth. Glucose 6-phosphate dehydrogenase (G6PD) was reported to increase its enzymic activity and mRNA expression by insulin both in vitro and in vivo.
11) Wagle et al. 12) suggested that the presence of PI3K and mTOR was necessary in the signal transduction pathway of G6PD expression by insulin from results of studies with various inhibitors for the signal pathways PD98059, wortmannin, LY294002, and rapamycin. Glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) were also reported to undergo increased expression by insulin treatment and this overexpression was deactivated by simultaneous addition of wortmannin. 13, 14) PI3K was demonstrated to participate in the signal pathway from insulin that controls expression of not only glycolytic enzymes but also glucose transporter 4, insulin-like growth factor-binding protein-1 (IGFBP-1), and Na ϩ /Pi-cotransporter- Caco-2 cells were incubated with or without various concentrations of (A) troglitazone, (C) tolbutamide, (E) buformin, and (F) metformin for 12 h and with (B) 100 mM troglitazone and (D) 100 mM tolbutamide for the period indicated. After total RNA was extracted, quantities of mRNA expression were analyzed by the real-time RT-PCR method. The results were normalized with the b-actin mRNA levels and the mRNA level of control was taken as 100%. Data represent the meanϮS.E. of five experiments. * pϽ0.05, ** pϽ0.01 vs. control. Fig. 3 . Effects of Epinephrine and Glucagon on mRNA Expression of AQP3 in Caco-2 Cells 1. [15] [16] [17] Lithium chloride, an inhibitor of GSK-3, was shown to restore expression of IGFBP-1 suppressed by insulin, suggesting that GSK-3 is necessary for regulating transcription of IGFBP-1.
18) Suppression of AQP3 transcription by insulin was found recovered by simultaneous addition of wortmannin and rapamycin, inhibitors for PI3K and mTOR, respectively, but no change was observed by lithium chloride in this study, suggesting that the signal transduction pathway from insulin for the expression of AQP3 includes PI3K and mTOR but not GSK-3.
Tumor necrosis factor-a (TNF-a) was reported to induce insulin resistance in skeletal muscles by continuous i.v. injection to rats, and is generally believed a causative agent inducing this resistance. 19) TNF-a causes increase of cellular ceramides and activation of PKC through activation of sphingomyelinase, and this activation causes phosphorylation of serine residues in insulin receptor substrate-1 (IRS-1). 20) Therefore tyrosine kinase activity of the insulin receptor is inhibited and insulin resistance appears to occur by stopping signal transduction from insulin. Since thiazolidinedione derivatives pioglitazone and troglitazone are ligands for peroxi- 
some proliferator activated receptor-g (PPAR-g), 21 ) the action mechanism of the derivatives has been proposed to restore the impaired function of IRS-1 by normalizing production of TNF-a. 22) Thus the derivatives improve signal transduction downstream of IRS-1 and the effect of insulin increase in target organs. 23) Troglitazone was reported to suppress mRNA expressions of G6Pase and PEPCK 24) and induce expression of GLUT4 in adipose cells. 25) mRNA expression of AQP3 in Caco-2 cells was found to decrease by treatment with troglitazone in this study. The suppressed expression was improved by simultaneous addition of wortmannin and rapamycin, suggesting that the signaling pathway from troglitazone partly shares the pathway from insulin downstream of IRS-1.
Epinephrine was observed to increase mRNA expression of AQP3. This increase was suppressed by simultaneous treatment with calphostin C, an inhibitor for protein kinase C (PKC), but not with H89, an inhibitor for protein kinase A (PKA), suggesting that the signaling pathway goes through PKC. Itoh et al. 6) reported that vasoactive internal polypeptide (VIP) induced increase of AQP3 expression in a human colonic epithelial cell line and that this phenomenon occurred through PKA. This may be explained by differences of the signal pathway between insulin and VIP in spite of involving increased AQP3 expression. Tolbutamide was observed to decrease mRNA expression of AQP3 and this may imply the possibility that the suppression mechanism of AQP3 expression by tolbutamide is partially similar to that of insulin. On the other hand, metformin and buformin did not suppress AQP3 expression, suggesting the possibility that the signaling pathways are different from each other. Despite epinephrine and glucagon exhibiting similar actions in that they raise blood glucose levels, glucagon did not affect expression of AQP3. This different effect on AQP3 expression between epinephrine and glucagon remains unclear. Glucagon receptor is known to couple with a Gs protein and the receptor signaling has been suggested mediated by PKA. 26) Since H89 did not affect increased expression of AQP3 by epinephrine, PKA may not be responsible for signaling of the AQP3 expression.
The signal pathway from insulin and troglitazone for regulation of AQP3 expression is predicted to pass through PI3K and mTOR in this study. Kishida et al. 7) observed suppression of AQP7 expression by treatment with insulin in adipose cells and investigated a promotor region for the gene transcription of AQP7. Although the pathways of AQP7 expression by insulin and its receptor signaling have not been elucidated yet, the similarity of the signal pathways between AQP3 and AQP7 expression controlled by insulin seems clear. Further studies are needed to elucidate the detailed mechanisms of the control of transcription of AQP3 mRNA, including identification of the signal transducers and specification of the promoter regions.
